Celgene's need for speed behind $500m antibody alliance with Sutro
This article was originally published in Scrip
Executive Summary
Sutro Biopharma hopes to announce one or two more collaborations with Big Pharma or large biotech companies within the next 12 months that will be similar to the San Francisco-based company's $500 million-plus deal with Celgene to design and develop novel antibody-drug conjugates (ADCs) and bi-specific antibodies for two undisclosed targets, and to manufacture an antibody from Celgene's early-stage pipeline.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.